BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/10/2014 4:18:00 PM | Browse: 273 | Download: 281
Publication Name World Journal of Hepatology
Manuscript ID 3235
Country of Manuscript Source United States
2013-04-16 07:59
Peer-Review Started
2013-04-16 10:36
To Make the First Decision
2013-05-14 18:45
Return for Revision
2013-05-17 10:46
2013-06-02 05:11
Second Decision
2013-06-09 13:25
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-06-10 04:35
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-07-22 15:25
Publish the Manuscript Online
2013-07-25 09:10
ISSN 1948-5182 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Autobiography
Article Title Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Adnan Muhammad, Manish Dhamija, Gitanjali Vidyarthi, Donald Amodeo, William Boyd, Branko Miladinovic and Ambuj Kumar
Funding Agency and Grant Number
Correspondence To Adnan Muhammad, MD, Department of Gastroenterology, University of South Florida, 12901 Bruce B. Downs Blvd, Tampa, FL 33620, United States. adnan_muhd@hotmail
Keywords Hepatocellular carcinoma; Transarterial chemoembolization; Sorafenib; Survival; Adverse events
Core Tip The incidence of hepatocellular carcinoma (HCC) is increasing and there is a need for better treatment modalities. Transarterial chemoembolization (TACE) and sorafenib are the main course of treatment for unresectable HCC. However there is an emphasis to combine them to improve survival. There is very limited data available to compare the effectiveness of TACE alone vs combination with sorafenib. Our results showed equal efficacy for both treatment arms without compromising adverse events. Child-Turcotte-Pugh classification and Barcelona Clinic Liver Cancer staging were significant predictors of survival. This study is the first reported in the literature comparing the outcome when treated with TACE alone vs TACE + sorafenib in United States patients.
Publish Date 2013-07-25 09:10
Citation Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, Miladinovic B, Kumar A. Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World J Hepatol 2013; 5(7): 364-371
Url http://www.wjgnet.com/1948-5182/full/v5/i7/364.htm
DOI http://dx.doi.org/10.4254/wjh.v5.i7.364
Full Article (PDF) WJH-5-364.pdf
Revised Manuscript 3235-Review.doc
Peer-review Report 3235-Peer reviews.pdf
Answering Reviewers 3235-Answering reviewers.pdf
Scientific Editor Work List 3235-Scientific editor work list.doc
Copyright License Agreement 3235-Copyright assignment.pdf